TSS
ALXN

Two Sigma Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Two Sigma Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,100
Closed -$698K – 2061
2020
Q3 		$698K Buy
6,100
+3,500
+135% +$378K 0.01% 471
2020
Q2 		$292K Buy
+2,600
New +$276K 0.01% 918
2020
Q1 		– Sell
-27,700
Closed -$3M – 2587
2019
Q4 		$3M Buy
27,700
+11,500
+71% +$1.23M 0.02% 580
2019
Q3 		$1.59M Buy
16,200
+10,100
+166% +$1.14M 0.01% 680
2019
Q2 		$799K Buy
6,100
+1,800
+42% +$232K 0.01% 841
2019
Q1 		$581K Sell
4,300
-6,700
-61% -$833K 0.01% 807
2018
Q4 		$1.07M Sell
11,000
-21,600
-66% -$2.55M 0.01% 607
2018
Q3 		$4.53M Sell
32,600
-400
-1% -$50.2K 0.03% 402
2018
Q2 		$4.1M Buy
33,000
+2,500
+8% +$292K 0.02% 563
2018
Q1 		$3.4M Buy
+30,500
New +$3.65M 0.02% 618

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's ALXN Position: Q1 2021 in Review

Two Sigma Securities sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,599 shares — an estimated $250K sold.

Two Sigma Securities first reported a position in ALXN in Q4 2015 and held it in 9 quarters. The position peaked at $1.95M in Q2 2018. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Two Sigma Securities reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Two Sigma Securities sold 1,599 Alexion Pharmaceuticals shares in Q1 2021, an estimated $250K.
  • Two Sigma Securities first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Two Sigma Securities's Alexion Pharmaceuticals position peaked at $1.95M in Q2 2018.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Two Sigma Securities's 13F filing for Q1 2021, filed 17 May 2021.